Moderna and Merck announce an investigational individualized neoantigen therapy
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Study efficacy measures will include the expression of dystrophin protein and motor function.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
Bourgoin early development hub broadens offerings for oral solid dose formulations
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Subscribe To Our Newsletter & Stay Updated